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Abstract: One of the most significant health issues is the disorders of mood according to the fact that they have a significant effect 
on the quality of life of the patients, their families, their working and wider social surroundings. According to the World Health 
Organization, mood disorders are the fourth cause of morbidity and mortality with a tendency to move to the second place by the 
2020. The prediction of higher number of patients diagnosed with depression in the future comes from the facts that the main factor 
of risk, like stress, is in constant rise. Furthermore, the demographic image (ageing of the population) is changing, associated with the 
effect of comorbidity of depression, also attributed with increase of the number of genetically predisposed patients with this mood 
disorder. The aim of this study is to define, describe and question the role of pharmacists in the treatment of patients suffering from 
depression. Therefore, we measured the impact of pharmaceutical care on significant parameters in treatment of depression due to the 
selection of appropriate therapy according to the guidelines, adherence of the patient, quality of life, work capability, anxiety, side 
effects and interactions with other medicines. 
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1. Introduction 
One of the most significant health issues is the 
disorders of mood according to the fact that they have 
a significant effect on the quality of life of the patients, 
their families, their working and wider social 
surroundings. According to the World Health 
Organization, mood disorders are the fourth cause of 
morbidity and mortality with a tendency to move to 
the second place by the 2020 [1, 2]. The prediction of 
higher number of patients diagnosed with depression 
in the future comes from the facts that the main factor 
of risk, like stress, is in constant rise. Furthermore, the 
demographic image (ageing of the population) is 
changing, associated with the effect of comorbidity of 
depression, also attributed with increase of the number 
of genetically predisposed patients with this mood 
disorder.  
Over 300 million people suffer from depression 
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globally. Depression was estimated to have its highest 
prevalence in high-income countries attributed with 
great and sudden social, economic and political 
changes accompanied by a weakening of social 
support [3, 4]. Poorer socio-economic and educational 
status and life in urban areas are the most frequent 
factors for development of these disorders [5]. Studies 
done in the Balkans showed that an additional 
problem is the fact that depression is most frequently 
unrecognized and therefore inadequately treated [6]. 
Many clinical studies confirmed that depression was 
significantly associated with female sex [7]. Therefore, 
this fact is associated with negative effects on family 
development and functioning, the role as a parent, and 
with the appearance of significant disorders in 
children [8, 9]. Comorbidity of depression with other 
disorders significantly deteriorates the somatic state of 
the patient [10, 11].  
The inability of administration of prescribed 
therapy in patients with diagnosed depression is often 
attributed with cessation/disruption of therapy and 
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inadequate treatment of depression. This consequently 
leads to frequent hospitalizations, incapability to work, 
marginalization, and stigmatization, by the community. 
Therefore, this is a frequent reason for suicides by 
patients suffering from depression [12]. The 
contribution of pharmacists in treatment of depression 
as experts in pharmacotherapy is huge. Pharmacists 
through an interdisciplinary approach and appliance of 
pharmaceutical care can affect the proper selection of 
therapy by monitoring the patient’s dosage regimens 
and detection of side effects associated with 
predisposition of depressive symptoms [13]. Keeping 
track of compliance and concordance in use of the 
medication for treatment of depression is of special 
importance. The development of pharmaceutical 
research studies, increase of pharmaceutical industry 
as well as the changes in healthcare systems and 
policies set additional challenges, which include 
continuous monitoring of the needs of patients as well 
as the trade and consumption of medications for the 
sake of rational medication administration.  
2. Materials and Methods 
The study is a randomised controlled clinical study 
in which a psychiatrist in General Hospital Tesanj will 
randomise patients according to the methods of random 
selection and the criteria of inclusion and exclusion 
defined in the protocol. The target population is adult 
patients 18 to 75 years old who suffer from diagnosed 
depressive episodes (according to the criteria set up for 
the diagnosis) and who are treated in General Hospital 
Tesanj (Bosnia and Herzegovina). A pharmacist will 
set up monthly appointments for the patients and 
educate them about depression and medications with a 
special review of side effects and interactions of 
medications. During this study, the pharmacist and the 
doctor will have two meetings where they will analyze 
observations of the pharmacist and evaluate the impact 
of pharmaceutical care with the intervention group. 
The standard group will only fill in the questionnaire 
about quality of life during their regular visit to the 
doctor at the beginning of the study, after three months 
and after six months of the study. For the purpose, we 
used the Patient Health Questionnaire (PHQ-9) which 
is a multipurpose instrument for screening, diagnosing, 
monitoring and measuring the severity of depression, 
modified for the needs of the hospital. Obtained results 
were verified by mental health professional, analyzed 
with SPSS software for statistical analysis of data and 
will include qualitative and quantitative elements. 
3. Results and Discussion 
Forty eight patients were monitored in this research, 
11 men and 37 women. We noticed that the incidence 
of depression is more frequent in women which is also 
presented in the research of WHO. During this 
research, three tests were conducted. The obtained 
data showed the significance of a pharmacist in the 
treatment of patients suffering from depression. 
Consideration of the anxiety test showed that the 
treatment with a team which includes a pharmacist 
compared to a team without a pharmacist presents 
progress in the treatment represented by a significant 
decrease in irritability and anxiety. And 56% of the 
patients had these symptoms during the first visit 
while this figure in the third visit was 4.3%. Results 
are presented on Fig. 1.  
When considering the questions from the life 
quality test we did not get significant results which 
showed us progress in the patient’s depression 
treatment with the presence of a pharmacist in an 
interdisciplinary team. Also, the patients’ life test 
showed important contribution of the pharmacists in 
the treatment of patients with depression. 
According to the obtained results, pharmacist 
should be included in the interdisciplinary team, 
which takes care of the treatment of patients with 
depression, and by further education of the pharmacist 
in the area of mental disorders, especially depression, 
even better results would be achieved. A research 
conducted in Belgium about the role of pharmacists in 
care of patients with depression showed that pharmacists 
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Fig. 1  Significance of a pharmacist in the treatment of patients suffering from depression.  
 
are not sufficiently involved in the treatment of this 
group patients attributed with insufficient education of 
the pharmacists regarding mental disorders [14].  
4. Conclusions 
Pharmacists are the most devoted health 
professionals. Patients visit pharmacists seven times 
more than they visit doctors. Pharmacists, as health 
professionals, could improve treatment outcomes by 
monitoring patients about side effects, effectiveness 
and by providing educational information about 
antidepressants. These data showed us that 
pharmacists through pharmaceutical care can make the 
fastest and the cheapest contribution to a good 
outcome of this multidisciplinary approach in the 
treatment of patients with depression. Unfortunately, 
lack of education about psychiatric disorders, minimal 
time for personalized care for patients and limited 
private spaces in the pharmacy to talk to patients 
about mental health issues are most common barriers 
for pharmacist in primary care for patients with 
depression.  
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